Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March
Live audio webcasts of both presentations will be available under “Events & Presentations” in the Investors & Media section of the Company’s website at www.rhythmtx.com. Replays of the webcasts will be available on the Rhythm website for 30 days following each presentation.
Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm’s lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm also supports
Stern Investor Relations, Inc.
Berry & Company Public Relations